Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in <i>KRAS</i>-Mutant Lung Adenocarcinoma
LKB1 loss is common in lung cancer, but no assay exists to efficiently evaluate the presence or absence of LKB1. We validated an IHC assay for LKB1 loss and determined the impact of LKB1 loss in KRAS-mutant non-small cell lung cancer (NSCLC).We optimized and validated an IHC assay for LKB1 (clone Le...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | англи |
| Хэвлэсэн: |
2015
|
| Онлайн хандалт: | https://doi.org/10.1158/1078-0432.ccr-14-3112 |
| Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|